Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

Article content
Article content
$124.2 million in cash and cash equivalents and marketable securities provides runway as of March 31, 2025
Article content
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025.
Article content
'During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline programs,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We announced a strategic partnership with DCx Biotherapeutics to out-license our discovery platforms, and we are exploring a full range of strategic alternatives and partnerships across our portfolio. We are well-positioned from an operational and financial standpoint to drive our clinical pipeline to key inflection points and remain on track to report initial data for both the LIONS and POLAR trials in the second half of this year.'
Article content
First Quarter 2025 and Recent Portfolio Highlights:
Article content
Announced out-licensing of its discovery platforms to DCx Biotherapeutics
Repare announced it out-licensed its early-stage discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'). In connection with this agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% equity position in DCx, including certain dilution protection rights, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low single-digit sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees.
Article content
RP-3467: Potential best-in-class, oral Polθ ATPase/helicase inhibitor
Repare is conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3647 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma.
Upcoming expected milestone:
Q3 2025: Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib.
Article content
RP-1664: First-in-class, oral selective PLK4 Inhibitor
Repare completed enrolment of 29 patients in its Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. LIONS is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664.
Upcoming expected milestone:
Article content
Lunresertib (RP-6306)
Repare is currently evaluating lunresertib in combination with Debio 0123, a highly selective, brain-penetrant, clinical WEE1 inhibitor, in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations as part of an ongoing 50/50 cost sharing collaboration with Debiopharm. Repare does not intend to continue to develop lunresertib in any other trials, absent securing a partnership with a development partner.
Article content
Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of March 31, 2025 were $124.2 million, as compared to $152.8 million as of December 31, 2024. The Company believes that its cash, cash equivalents, and marketable securities are sufficient to fund its current operational plans through 2027.
Revenue from collaboration agreements: Revenue from collaboration agreements was nil and $52.4 million for the three months ended March 31, 2025 and 2024, respectively.
Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $20.3 million and $33.0 million for the three months ended March 31, 2025 and 2024, respectively.
General and administrative (G&D) expenses: G&A expenses were $7.7 million and $8.6 million for the three months ended March 31, 2025 and 2024, respectively.
Net income (loss): Net loss was $30.1 million, or $0.71 per diluted share, and $13.2 million, or $0.30 per diluted share, for the three months ended March 31, 2025 and 2024, respectively.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of its discovery platforms to DCx, including the potential benefits of the transaction and the receipt of out-licensing, clinical and commercial milestone payments and royalties under the out-license agreement; the Company's plans for exploring strategic alternatives and partnerships across the clinical portfolio, including the Company's plans to seek a partner to fund further clinical development of lunresertib and other assets; the Company's anticipated cash runway; the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company's product candidates including the advancement of its three ongoing clinical trials. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025., and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Globe and Mail

2 hours ago

• Globe and Mail

CanadaBis Capital With its wholly owned Sub. (STIGMA GROW) Announces Record Revenue Q1 F2025 Resulting in $9.6M Gross with $321,569 in NET Earnings and an Adjusted EBITDA of $675,892

CALGARY, AB , Dec. 31, 2024 /CNW/ - CanadaBis Capital (the "Company" or "CanadaBis Capital") (TSXV: CANB.V) a premium cannabis and concentrates producer, is pleased to announce its First Quarter Fiscal 2025 financial results for the three month period ending October 31, 2024 . "Our Brands continue to deliver products that are in demand, and our dedication towards our quality continue to prove our strength in the market.", said Travis McIntyre , CEO of CanadaBis. "While we continue to focus on profitability, we are delighted to be able to post yet another record quarter of revenue. Our product launch momentum also continues to accelerate with Multiple new products launched this quarter. We exit Q1 F2025 with our most aggressive and innovate pipeline of new products in the Company's history. Financial Highlights The Company realized its Record gross revenue of $9.6 million for October 31, 2024 , and 7% higher than the same corresponding period of 2023. The Company achieved positive net income of $321,569 for the three months ended October 31, 2024 . The Company continues to market its Resin Infused Pre-rolls, Shatter Infused Pre-rolls, Resin Infused Flower, along with Moonrocks (Moonrocks are whole flower, coated in resin and rolled in kief). The Company was able to maintain sales of its newest product line, Super Slim Cigarette Style Pre-Rolls, the Electric Dartz. These new products were packaged in 10 packs 0.4 grams per roll both infused and non infused. Adjusted EBITDA also showed positive earnings with $675,892 for the three months Stigma Grow's deep innovation sales pipeline is showcased by the consistent launch of new SKU's and new products driven by customer demand. The Company sold over 570,000 units of combined concentrate and dry flower for the three months ended October 31, 2024 , a 4% increase compared to the 550,000 units sold over the corresponding period in 2024. The Company continues to manage its input expenses through negotiation with multiple suppliers to save costs while increasing concentrate yields. The Company is in the process of shipping its first international sales to Europe . The expectation is that this would be the next significant phase of the Company's mission in growth and new geographic area of existing revenue stream for Cultivation and Wholesale. Stigma Grow also continues to re-formulate its concentrate lines to meet current clients' demands to maintain larger terpene and cannabinoid profiles across the lineup. Negotiations with other Cannabis Cultivators are ongoing by the Company which has allowed significant reduction in costs, a trend that is expected to continue through 2025 as more Cultivators reposition themselves in the industry The Company announced the launch of the latest addition to the Dab Bods brand lineup – a groundbreaking 60%+ double-infused pre-roll. This new offering sets a new benchmark for THC potency in the Canadian market. Dab bods Brand continues to grow with the demand across Cananda and is will be launching 2 new exciting products in the DAB N DIPS and the CANADAS 1st DAB N GO both products will revolutionize the way cannabis is consumed by offering discreet usage. QUARTERLY HIGHLIGHTS • Adjusted EBITDA is a Non-GAAP performance measure. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" for further details. Presenting Adjusted EBITDA only for the three and six months ended October 31, 2024. EBITDA calculation shown by entity to present the breakdown of each entity. General Overall gross revenues for the period ended October 31, 2024 increased to $9.6 million from $9.0 million in the corresponding period of 2024. This increase was due to continued growth and demand from new and existing SKUs launched under the Dab Bod Brands and the industry's demand for new innovative products such as the +60s Pre-rolls and our famous milled flower and Dartz . Net revenue of $5.1 million compared to $5.7 million for the corresponding period of 2024 or 11.74% decrease. Net Revenue for Q1 2025 of $5.1 million increased over Q4 2024 of $3.9 million by $1.2 million or 31%. The Company has experienced growth in the existing Provinces due to both new launches and the performance of existing products. The Company has released several versions of the new cigarette style pre-roll in infused and non-infused as well as the new " Dap N Go" that has been well received in the concentrate space. The Province of Manitoba has seen higher increases from our new and existing products. See Segmented Reporting section to this MD&A, for a more detailed discussion. The Company was able to initiate more cost savings initiatives during Q1 2025, through cost savings by renegotiating input material pricing while also implementing new procedures in its production lines to cut and manage operational costs. Management is of the expectation that these new initiatives will be realized throughout 2025. Given the Company's position as a vertically integrated Cannabis company/producer, management will continue to adjust internal strategy based on external factors causing fluctuations in either selling prices of products/services and input cost of products and services to ensure capacity allocation is being optimized on products/services in highest demand, while ensuring mandated gross profit margins are being achieved. Management notes that the current climate of Cannabis industry is extremely competitive and saturated with multiple products across the Nation. The Company has several competitive advantages to ensure long-term success within the industry. In the short-term, this relates primarily with respect to our butane hydrocarbon (BHO) extraction process. Management continues to explore various concentrate products to diversify it offer to the market by formulating new products to meet demand. About CanadaBis Capital Inc. CanadaBis Capital Inc. ( TSXV:CANB ) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth in the global cannabis market – with specific attention paid to supplying the fast-emerging concentrates category through their Stigma Grow cultivation and BHO extraction facility. Subsidiaries: Stigma Pharmaceuticals Inc. – 100% held; 1998643 Alberta Ltd. (operating as "Stigma Grow") - 100% held; include cultivation and wholesale, extraction and tolling Full Spectrum Labs Ltd. (operating as "Stigma Roots") - 100% held; 2103157 Alberta Ltd. (operating as "INDICAtive Collection") -100% held; the retail operation, and Goldstream Cannabis Inc. - 95% held. Acting as the cornerstone for everything they offer, Stigma Grow continuously strives to address the market demands and lingering stigmas within the legal cannabis industry head-on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada's legal cannabis industry. For more information on CanadaBis Capital or Stigma Grow visit: CAUTIONARY STATEMENT Non-GAAP Measures This news release contains the financial performance metric of Adjusted EBITDA, a measure that is not recognized or defined under IFRS (a "Non-GAAP Measure"). As a result, this data may not be comparable to data presented by other cannabis companies. For an explanation and reconciliation of Adjusted EBITDA to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the MD&A for the three and six months ended Oct 31, 2024. The Company believes that Adjusted EBITDA is a useful indicator of operational performance and is specifically used by management to assess the financial and operational performance of the Company. Adjusted EBITDA is a measure of the Company's financial performance. It is intended to provide a proxy for the Company's operating cash flow and is widely used by industry analysts to compare CanadaBis to its competitors and derive expectations of future financial performance of the Company. Adjusted EBITDA increases comparability between comparative companies by eliminating variability resulting from differences in capital structures, management decisions related to resource allocation, and the impact of fair value adjustments on biological assets, inventory, and financial instruments, which may be volatile on a period-to-period basis. Adjusted EBTIDA is not a recognized, defined, or standardized measure under IFRS. The Company calculates Adjusted EBITDA as net income (loss) and comprehensive income (loss) excluding changes in fair value of biological assets, change in fair value of biological assets realized through inventory sold, depreciation and amortization expense, share-based payments, and finance costs. REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include but are not limited to statements with respect to our business and operations; timing of the Sundial products coming to market; the demand and market for live-resin vape cartridges, and our general business plans. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company's products to compete with the pricing and product availability on the black-market; the market demand for the Company's products; and assumptions concerning the Company's competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company's continuous disclosure on SEDAR at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

CTV News

7 hours ago

• CTV News

Vancouver lawyer suspended for submitting false documents in support of client's $3.3M loan application

A Vancouver lawyer has admitted to improperly notarizing documents and solemnly declaring affidavits that contained information he knew was false in order to help a corporate client secure a $3.3-million loan from a U.S. bank. Jason Chieh-Sheng Wang admitted his misconduct in a consent agreement with the Law Society of B.C., a summary of which was published online last week. According to the document, Wang was retained by 'a group of companies' in April 2023 to facilitate the loan application. 'Upon being retained, the lawyer was advised that the client was in difficult financial circumstances, and that it wished to obtain a loan from the lender on an urgent basis,' the summary reads. The loan was secured by 'five pieces of artwork as collateral,' according to the document. None of the parties involved in the situation – other than Wang himself – are named in the consent agreement summary. Instead, the document uses parties' initials. 'The loan was personally guaranteed by ZYZ and JM, whose respective families held the majority of the shares of the client,' the document reads. 'The loan also required the approval of their respective spouses, YP and LW, documented by spousal consents.' The lender told Wang it needed the spousal consent forms – along with other documents prepared in the U.S. – notarized, something the lawyer said would be impractical because some of the parties whose signatures were required were located in China. The bank eventually agreed that Wang could notarize the signatures in question via video call. Wang 'purported to notarize' four documents on May 15, 2023, but he had not actually met the signatories via video call, or at all, according to the consent agreement summary. The lawyer also created three affidavits in which he swore that the signatories had joined him on a video call and shown him both sides of their government-issued photo IDs before signing the documents. 'The lawyer solemnly declared the contents of the affidavits of execution to be true when he knew that he had not met with any of the signatories … via video conference or at all, and had not witnessed any of their signatures,' the summary reads. Wang also admitted to deleting WeChat messages he had exchanged with the client's representatives, in which he agreed to proceed with notarizing the documents without the requisite video call. 'The lawyer knew or ought to have known that deleting this client correspondence was contrary to his obligation to maintain and preserve his client's files and records," the summary reads. For all of this admitted misconduct, Wang agreed to serve a one-month suspension, which began on June 16. In accepting the consent agreement, the law society's discipline panel considered three mitigating factors:

CTV News

8 hours ago

• CTV News

Sudbury appoints 3 new GMs, streamlines city structure

The City of Greater Sudbury announced the appointment of three new general managers and a revised organizational structure on Thursday, marking a shift in municipal leadership aimed at improving efficiency and service delivery. The appointments follow a national search led by Odgers Canada. Shari Lichterman, the city's chief administrative officer, hired in February, also announced structural changes, including consolidating two divisions, eliminating three director roles, and creating a new Community Services department. The revisions are expected to yield cost savings while separating the fire chief and paramedic chief roles. City of Greater Sudbury's New Organizational Structure Effective July 7, 2025, the City of Greater Sudbury is implementing a new organizational structure that marks a shift in municipal leadership aimed at improving efficiency and service delivery. The structural changes include consolidating two divisions, eliminating three director roles, and creating a new Community Services department. (Supplied/City of Greater Sudbury) Planning and Growth Kris Longston An undated promotional photo of Kris Longston, the City of Greater Sudbury's new General Manager of Planning and Growth. (Supplied/City of Greater Sudbury) Kris Longston, promoted to General Manager of Planning and Growth, brings 23 years of municipal experience – including 16 with the city, most recently as director of planning services. In that role, he led initiatives such as the Housing Supply Strategy and Climate Action Plan. Community Well-being Tyler Campbell An undated promotional photo of Tyler Campbell, the City of Greater Sudbury's new General Manager of Community Well-being. (Supplied/City of Greater Sudbury) Tyler Campbell, the new General Manager of Community Well-being, has worked with the city since 2011, previously serving as director of children and social services. His leadership includes projects like the rollout of the Canada-wide Early Learning and Child Care program. Community Infrastructure Antti Vilkko An undated promotional photo of Antti Vilkko, the City of Greater Sudbury's new General Manager of Community Infrastructure. (Supplied/City of Greater Sudbury) Antti Vilkko, joining as General Manager of Community Infrastructure on July 28, has over 25 years of engineering management experience, including seven years as general manager of facilities and energy management for the City of Guelph. Exciting changes Shari Lichterman An undated profile photo of Greater Sudbury CAO Shari Lichterman. (LinkedIn) 'I'm excited to welcome Kris, Tyler and Antti into their new roles and to fill these important leadership vacancies, building on our strong staff team here at the City,' said Lichterman, in a news release. 'The changes demonstrate our commitment to finding efficiencies and ensuring our resources are focused on delivering the services our community needs.' Greater Sudbury Mayor Paul Lefebvre An undated profile photo of Greater Sudbury Mayor Paul Lefebvre. (File photo/City of Greater Sudbury) Mayor Paul Lefebvre praised the appointments, stating, 'Each brings valuable experience and perspective to our executive leadership team. As the structure evolves to meet the changing needs of our community, I remain optimistic about what we can achieve together in building a city where people want to live, work, play and invest.' The new structure takes effect July 7.